Semaglutide vs Tirzepatide
Semaglutide (GLP-1 receptor agonist) and Tirzepatide (Dual GIP/GLP-1 receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Compound class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | 31 amino acids | 39 amino acids |
| Molecular weight | 4113.6 g/mol | 4813.5 g/mol |
| Half-life | ~7 days | ~5 days |
| Origin | Developed by Novo Nordisk as a long-acting analog of the human incretin hormone GLP-1, building on the earlier once-daily liraglutide. It received first regulatory approvals in 2017 (injectable) and 2019 (oral). | Developed by Eli Lilly as the first approved dual agonist targeting both the GIP and GLP-1 receptors. It received first FDA approval in 2022. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Semaglutide works
Semaglutide is a structurally modified analog of native glucagon-like peptide-1 (GLP-1) that binds and activates the GLP-1 receptor. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central appetite-regulating pathways to reduce food intake. Its backbone modifications and a C18 fatty-acid (diacid) side chain promote albumin binding and resistance to DPP-4 degradation, giving it a prolonged duration of action.
How Tirzepatide works
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Combined agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake. It carries a C20 fatty-diacid moiety enabling albumin binding and a prolonged half-life supporting once-weekly administration.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
Semaglutide
Tirzepatide
What sets each apart
Semaglutide
Unlike dual or triple agonists, semaglutide is a selective GLP-1 receptor agonist. Its once-weekly dosing and availability in an oral form distinguish it from the older once-daily liraglutide.
Tirzepatide
Tirzepatide differs from semaglutide and other single GLP-1 agonists by simultaneously engaging the GIP receptor, a mechanism proposed to contribute to its metabolic effects.
Frequently asked questions
How does semaglutide differ from tirzepatide?
Semaglutide is a single-receptor GLP-1 agonist, whereas tirzepatide is a dual GLP-1/GIP receptor agonist. In head-to-head research the dual-agonist mechanism is associated with larger effects on body weight and glycemic endpoints in the models studied. Semaglutide remains the more extensively characterized reference compound.
What is semaglutide and what receptor does it target?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist derived from the native GLP-1 peptide with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin to extend its half-life. In research it is studied as a reference GLP-1 agonist in models of glucose regulation, appetite/food intake, and body-weight change. It is the mono-agonist against which many newer multi-receptor compounds are benchmarked.
What does semaglutide's long half-life mean for research design?
Semaglutide has a reported plasma half-life of roughly 7 days (about 155-184 hours), which is why once-weekly administration is used in the published literature. Steady-state concentrations are typically reached after about 4-5 weeks at a given dose level, so study designs generally include a multi-week dose-escalation before any maintenance-phase readout. This slow kinetics also means washout after discontinuation spans several weeks.
What is tirzepatide and how is its mechanism different from a GLP-1 mono-agonist?
Tirzepatide is a dual agonist that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors from a single synthetic peptide backbone with a C20 fatty-diacid for half-life extension. The added GIP activity is the key distinction from GLP-1-only agonists like semaglutide. It is studied in models of glucose handling, appetite, and body-weight change.
What is tirzepatide's half-life and what does it imply for study design?
Tirzepatide has a reported half-life of about 5 days (~117 hours), supporting once-weekly administration in the literature. Steady state is generally reached after about 4 weeks at a given dose, so protocols include a multi-week escalation before maintenance-phase readouts. The multi-day half-life also means a washout of several weeks after discontinuation.
How is tirzepatide dose-escalated in research protocols?
Published protocols escalate weekly from 2.5 mg upward through 5, 7.5, 10, 12.5 and up to 15 mg once weekly, with each step commonly held about 4 weeks. As with other incretin agonists, escalation is used to limit gastrointestinal tolerability issues. These are reference figures for research context only, not human dosing guidance.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.